| Type | MGI:General | Description | MOG35-55-treated mice exhibit increased disease severity with increased demyelination compared with similarly treated wild-type mice leukocytes from MOG35-55-treated mice exhibit increased nitric oxide levels and myeloid-specific pro-inflammatory cytokines (IL1a, IL1b, and IL12) compared with cells from similarly treated wild-type mice |
